Duloxetine Improves Spinal Cord Stimulation Outcomes for Chronic Pain
| Autor: | Marisa DiMarzio, Julia Prusik, Michael Gillogly, Shelby Sabourin, Tarun Prabhala, Julie G. Pilitsis |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Gabapentin Pregabalin Duloxetine Hydrochloride 03 medical and health sciences chemistry.chemical_compound Disability Evaluation 0302 clinical medicine medicine Duloxetine Humans Aged Pain Measurement Psychiatric Status Rating Scales Analgesics Analysis of Variance Spinal Cord Stimulation integumentary system Dose-Response Relationship Drug business.industry Chronic pain Beck Depression Inventory General Medicine Middle Aged medicine.disease humanities Oswestry Disability Index Anesthesiology and Pain Medicine Treatment Outcome nervous system Neurology chemistry McGill Pain Questionnaire Anesthesia Regression Analysis Pain catastrophizing Female Neurology (clinical) Chronic Pain business tissues 030217 neurology & neurosurgery medicine.drug Follow-Up Studies |
| Zdroj: | Neuromodulation : journal of the International Neuromodulation Society. 22(2) |
| ISSN: | 1525-1403 |
| Popis: | OBJECTIVE Spinal cord stimulation (SCS) has been shown to be effective in treating chronic pain in patients with varying etiologies. However, the impact of pharmacological treatment on augmenting response to SCS has not been previously studied. METHODS We enrolled 108 patients who had undergone SCS surgery and documented their pain preoperatively and at 12 months postoperatively using the Numeric Rating Scale (NRS), McGill Pain Questionnaire (MPQ), Beck Depression Inventory (BDI), Oswestry Disability Index (ODI), Pain Catastrophizing Scale (PCS), and Global Impression of Change (GIC). Pain outcomes were compared between patients receiving SCS alone and in addition to duloxetine. RESULTS At 1-year follow-up, patients receiving duloxetine and SCS (n = 41) had better pain relief in the affective component of MPQ (p < 0.05) than those receiving SCS alone (n = 71). Patients on duloxetine with SCS also were significantly more willing to receive SCS again (p < 0.01). This willingness appeared to be duloxetine dose dependent (p < 0.05). Patients receiving pregabalin or gabapentin with SCS did not have significantly more pain relief than patients receiving SCS alone. CONCLUSION This study shows the combination therapy to be an effective strategy to provide more holistic pain relief and further improve the quality of life of SCS patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect